-
.
- Bristol-Myers Squibb Carbon Monoxide BMY introduced three-year follow-up outcomes from the Stage 3 CheckMate -274 Stage 3 test of Opdivo contrasted to sugar pill for muscle-invasive urothelial cancer at a high threat of reoccurrence after extreme resection.
- Opdivo greater than increased the typical size of time clients lived without illness reoccurrence, showing a typical healthsome survival of 22.0 months contrasted to 10.9 months with a sugar pill. Clients whose growth cells shared PD-L1 ≥ 1% stayed healthsome for greater than 6 times as long as sugar pill.
- Associated: Revlimid Generic Competitors Injures Bristol Myers’ Q4 Revenues, Problems Yearly Expectation Within Expected Array
- Opdivo revealed a typical NUTRFS, specified as the moment clients lived without illness reoccurrence beyond the bladder, ureters, or kidney hips, of 25.9 months contrasted to 13.7 months for sugar pill.
- Mean DMFS, specified as the moment clients live without cancer cells dispersing from the key growth to remote body organs or lymph nodes, was 47.1 months with Opdivo vs. 28.7 months with sugar pill.
- Cost Activity: BMY shares are up 0.21% at $71.00 on the last check Friday.
.
.
.
.
.
.
© 2023 Benzinga.com. Benzinga does not supply financial investment recommendations. All legal rights booked.
